ClinicalTrials.gg
Not yet recruitingNCT07395830Updated Feb 10, 2026

Effects of a Multisensory VR Experience on Stress and User Experience

An interventional study of Relaxing aroma and state of stress/calm in To Evaluate the Main Effects of Varying Auditory Stimuli and To Evaluate the Main Effects of Varying Olfactory Stimuli, sponsored by Universidad de Zaragoza. Not yet recruiting. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Universidad de Zaragoza · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Study summary

This study explicitly tests a multisensory virtual reality experience that combines visual, auditory, and olfactory channels to modulate the stress response in young adults. In addition to visual and auditory stimulation, the study also assesses whether a relaxing olfactory stimulus attenuates this effect. The environment and task remain constant (constant visuals); auditory and olfactory elements are varied. Objective. To evaluate the main effects of varying auditory and olfactory stimuli, as well as their interaction, on variables related to the performance of a quiz-type task in virtual reality.

02

Conditions studied

  • To Evaluate the Main Effects of Varying Auditory Stimuli
  • To Evaluate the Main Effects of Varying Olfactory Stimuli
03

In context

Lead sponsor

Universidad de Zaragoza is the lead sponsor of 111 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • must meet the required age.
  • must have corrected vision/hearing.

Exclusion criteria

Exclusion Criteria:

  • uncontrolled asthma.
  • uncontrolled odor-triggered migraines.
  • pregnancy state.
  • nasal congestion.
  • severe predisposition to dizziness in virtual reality.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • No intervention
    Control

    Control Group

  • Experimental
    Experimental

    Experimental Group

    Other: Relaxing aroma and state of stress/calm

Interventions

  • OtherRelaxing aroma and state of stress/calm

    A 2×2 randomized design is used. The Aroma condition is between subjects (relaxing aroma vs. no aroma) (experimental group and control group). The Mode condition is within each group and consists of two blocks: Stress and Calm. The order of the blocks is counterbalanced (Stress-Calm/Calm-Stress): half of the participants experience Stress first and then Calm, and the other half in the reverse order.

06

What researchers measure

Primary outcomes

  1. NASA Task Load Index

    This test measures perceived mental workload. It has the following dimensions: Mental demand, effort, physical demand, performance, time constraints, and frustration level. Scoring interpretation: Higher scores for mental demand, effort, physical demand, time constraints, and frustration level indicate a greater workload/demand. Higher performance indicates a better experience. Reference: S. G. Hart y L. E. Staveland, "Development of NASA-TLX (Task Load Index): Results of Empirical and Theoretical Research", en Advances in Psychology, vol. 52, North-Holland, 1988, pp. 139-183. doi: 10.1016/S0166-4115(08)62386-9.

    Time frame: From enrollment to the end of treatment at 2 weeks

  2. Short Stress State Questionnaire (SSSQ)

    Test to measure stress levels. It has three dimensions: engagement, anxiety, and worry. Scoring interpretation: * Higher score in anxiety/worry -\> worse (more stress) * Higher score in engagement -\> better (more involvement/functional activation) Reference: W. S. Helton y K. Näswall, "Short Stress State Questionnaire", Eur. J. Psychol. Assess., vol. 31, n.o 1, pp. 20-30, jun. 2015, doi: 10.1027/1015-5759/a000200.

    Time frame: From enrollment to the end of treatment at 2 weeks

Secondary outcomes

  1. IPQ - Igroup Presence Questionnaire

    A test that measures overall presence in VR. Dimensions: Spatial presence, engagement, realism. Scoring logic: Higher scores indicate greater presence. Reference: T. Schubert, F. Friedmann, and H. Regenbrecht, "The Experience of Presence: Factor Analytic Insights," Presence Teleoperators Virtual Environ., vol. 10, no. 3, pp. 266-281, June 2001, doi: 10.1162/105474601300343603.

    Time frame: From enrollment to the end of treatment at 2 weeks

  2. VRSQ - Virtual Reality Sickness Questionnaire

    It measures Cybersickness / motion sickness symptoms. Dimensions: General malaise, vestibular symptoms. Scoring logic: Higher scores indicate greater malaise. Reference: H. K. Kim, J. Park, Y. Choi, and M. Choe, "Virtual reality sickness questionnaire (VRSQ): Motion sickness measurement index in a virtual reality environment," Appl. Ergon., vol. 69, pp. 66-73, May 2018, doi: 10.1016/j.apergo.2017.12.016.

    Time frame: From enrollment to the end of treatment at 2 weeks

  3. VAS Scale

    It measures: * Odor intensity (experimental only) * Odor liking (experimental only) * Odor familiarity (experimental only) * Perceived time pressure (both groups) Meaning: Higher scores indicate greater perceived intensity/liking/familiarity/pressure (depending on the item). Reference: M. Koo y S.-W. Yang, "Visual Analogue Scale", Encyclopedia, vol. 5, n.o 4, nov. 2025, doi: 10.3390/encyclopedia5040190.

    Time frame: From enrollment to the end of treatment at 2 weeks

  4. UEQ-S - User Experience Questionnaire Short

    It masures the user experience. Dimensions: Pragmatic and hedonic. Scoring logic: Higher scores indicate better user experience. Reference: M. Schrepp, A. Hinderks, and J. Thomaschewski, "Design and Evaluation of a Short Version of the User Experience Questionnaire (UEQ-S)," Int. J. Interact. Multimed. Artif. Intell., vol. 4, no. 6, pp. 103-108, Dec. 2017.

    Time frame: From enrollment to the end of treatment at 2 weeks

  5. Performance rate

    Measures of the number of correct answers, response time, and use of clues

    Time frame: From enrollment to the end of treatment at 2 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07395830
Responsible party
Guillermo Palacios (PhD, Universidad de Zaragoza) — Principal investigator
First posted
Feb 9, 2026
Start date
Feb 10, 2026 (estimated)
Primary completion
Apr 1, 2026 (estimated)
Completion
May 1, 2026 (estimated)
Last update
Feb 10, 2026

Study contacts

Guillermo Palacios, PhD
Contact
guillermo.palacios@unizar.es
+34978618179

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion